万古霉素的耐药机制.pdfVIP

S U P P L E M E N T A R T I C L E Telavancin: Mechanisms of Action, In Vitro Activity, and Mechanisms of Resistance James A. Karlowsky,1,2 Kim Nichol,2 and George G. Zhanel1 1Department of Medical Microbiology, College of Medicine, University of Manitoba, and 2Diagnostic Services Manitoba, Winnipeg, Canada Telavancin is a semisynthetic lipoglycopeptide derivative of vancomycin. Telavancin has a dual mechanism of antibacterial action, disrupting peptidoglycan synthesis and cell membrane function. In 2014, the Clinical and Laboratory Standards Institute (CLSI) revised the antimicrobial susceptibility testing method for telavancin, resulting in minimum inhibitory concentration (MIC) determinations that are more accurate and reproducible and demonstrate greater in vitro potency than shown with the previous testing method. The CLSI testing meth- od changes coincided with revised telavancin MIC interpretive break point criteria for susceptibility approved D o by the US Food and Drug Administration for Staphylococcus aureus (≤0.12 µg/mL), Streptococcus pyogenes w n l